Vandetanib, VEGFR2 tyrosine kinase inhibitor (ab142099)

Overview

  • Product name

    Vandetanib, VEGFR2 tyrosine kinase inhibitor
  • Description

    Orally available, potent VEGFR2 tyrosine kinase inhibitor
  • Alternative names

    • 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxy]quinazoline
    • Caprelsa®
    • CH 331
    • Zactima
    • ZD 6474
    • ZD6474
    see all
  • Biological description

    Orally available, potent VEGFR2 tyrosine kinase inhibitor (KDR IC50 = 40 nM). Also inhibits fms-like tyrosine kinase 4 (VEGFR3, IC50 = 110 nM) and epidermal growth factor receptor (EGFR/HER1, IC50 = 500 nM) but shows selectivity against a panel of other tyrosine and serine-threonine kinases. Displays anti-angiogenesis activity.

  • Purity

    > 98%
  • CAS Number

    443913-73-3
  • Chemical structure

    Chemical Structure

Properties

  • Chemical name

    N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy] quinazolin-4-amine
  • Molecular weight

    475.35
  • Molecular formula

    C22H24BrFN4O2
  • PubChem identifier

    3081361
  • Storage instructions

    Shipped at Room Temperature. Store at -20°C. Store under desiccating conditions.
  • Solubility overview

    Soluble in DMSO to 50 mM and in ethanol to 10 mM
  • Handling

    Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20°C. Generally, these will be useable for up to one month. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

    Need more advice on solubility, usage and handling? Please visit our frequently asked questions (FAQ) page for more details.

  • SMILES

    CN1CCC(CC1)COC2=C(C=C3C(=C2)N=CN=C3NC4=C(C=C(C=C4)Br)F)OC
  • Source

    Synthetic

References

This product has been referenced in:

  • Morabito A  et al. Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. Oncologist 14:378-90 (2009). Read more (PubMed: 19349511) »
  • Herbst RS  et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 16:239-49 (2007). Read more (PubMed: 17243944) »
  • Ciardiello F  et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 9:1546-56 (2003). Read more (PubMed: 12684431) »
  • Wedge SR  et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645-55 (2002). Read more (PubMed: 12183421) »

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab142099.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES, NOT FOR USE IN HUMANS"
For licensing inquiries, please contact partnerships@abcam.com

Sign up